Detecting protein aggregates on untreated human tissue samples by atomic force microscopy recognition imaging.
We apply topography and recognition (TREC) imaging to the analysis of whole, untreated human tissue for what we believe to be the first time. Pseudoexfoliation syndrome (PEX), a well-known cause of irreversible blindness worldwide, is characterized by abnormal protein aggregation on the anterior lens capsule of the eye. However, the development of effective therapies has been hampered by a lack of detailed knowledge of the protein constituents in these pathological deposits and their distribution. Using both TREC and immunofluorescence, one of the proteins implicated in the PEX pathology--the apolipoprotein clusterin--was detected, and differences in its distribution pattern on the surface of untreated human lens capsule tissue in both PEX and normal control samples were investigated. Our study shows the potential of TREC imaging for the analysis of whole, untreated human tissue samples.
Creasey
Rhiannon
R
School of Chemical and Physical Sciences, Flinders University, Bedford Park, Australia.
Sharma
Shiwani
S
Craig
Jamie E
JE
Gibson
Christopher T
CT
Ebner
Andreas
A
Hinterdorfer
Peter
P
Voelcker
Nicolas H
NH
D000906:Antibodies / Q000276:immunology; D051152:Clusterin / Q000737:chemistry* / Q000276:immunology / Q000378:metabolism*; D017889:Exfoliation Syndrome / Q000175:diagnosis / Q000378:metabolism / Q000473:pathology; D005455:Fluorescent Antibody Technique; D006801:Humans; D007903:Lens Capsule, Crystalline / Q000378:metabolism; D018625:Microscopy, Atomic Force / Q000379:methods*; D057054:Molecular Imaging / Q000379:methods*; D055503:Protein Multimerization; D020836:Protein Structure, Quaternary
D000906:Antibodies; D051152:Clusterin
Curr Opin Ophthalmol. 2008 Mar;19(2):95-101
18301281
Trans Am Ophthalmol Soc. 1953;51:385-407
13216790
Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1447-57
17389470
Nanotechnology. 2009 May 27;20(21):215103
19423924
Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3742-52
16186358
Biophys J. 2007 Jul 15;93(2):L11-3
17496017
Acta Ophthalmol Scand. 2007 Dec;85(8):810-21
17376188
Exp Eye Res. 2009 Feb;88(2):151-64
18773892
Prog Retin Eye Res. 2000 May;19(3):345-68
10749381
Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12503-7
15314231
Nat Genet. 2004 Feb;36(2):178-82
14745449
Exp Eye Res. 2009 Apr;88(4):776-85
18809397
J Mol Biol. 2007 Nov 16;374(1):162-9
17920625
Bioconjug Chem. 2007 Jul-Aug;18(4):1176-84
17516625
Exp Eye Res. 2009 Oct;89(4):479-85
19442659
Nano Lett. 2008 Dec;8(12):4312-9
19367846
Biophys J. 2004 Sep;87(3):1981-90
15345574
Invest Ophthalmol Vis Sci. 2009 Jun;50(6):2796-801
19182256
Top Curr Chem. 2008;285:29-76
23636675
Nano Lett. 2009 Feb;9(2):571-5
19115834
Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3477-81
8622961
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4005-10
10759550
Microsc Res Tech. 2000 Aug 15;50(4):305-15
10936885
Am J Ophthalmol. 2006 May;141(5):921-937
16678509
Mol Vis. 2008 Sep 22;14:1727-36
18806885
Chemphyschem. 2005 May;6(5):897-900
15884073
Hum Mol Genet. 2008 Mar 1;17(5):710-6
18037624
Ophthalmology. 2008 Apr;115(4):614-619.e2
17698197
Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1978 Mar 7;205(4):213-20
207195
Science. 2007 Sep 7;317(5843):1397-400
17690259
Acta Ophthalmol (Copenh). 1989 Dec;67(6):724-6
2618644
Cell Tissue Res. 1997 Apr;288(1):111-8
9042778
Pflugers Arch. 2008 Apr;456(1):247-54
18286302
Graefes Arch Clin Exp Ophthalmol. 2001 Dec;239(12):952-60
11820702
J Neurochem. 2004 Jul;90(2):502-12
15228606
Exp Eye Res. 2006 Apr;82(4):545-57
16386733
Micron. 2007;38(5):446-61
17015017
Invest Ophthalmol Vis Sci. 2006 May;47(5):1982-90
16639006
Nanotechnology. 2008 Sep 24;19(38):384017
21832576
Phys Rev Lett. 1986 Mar 3;56(9):930-933
10033323
Nat Genet. 2009 Oct;41(10):1094-9
19734903
Int J Biochem Cell Biol. 2002 May;34(5):427-31
11906815
Invest Ophthalmol Vis Sci. 1997 Apr;38(5):970-84
9112993
Ultramicroscopy. 2007 Oct;107(10-11):922-7
17560033
Nat Methods. 2006 May;3(5):347-55
16628204
Annu Rev Biophys Biomol Struct. 1994;23:115-39
7919779